search
Back to results

Psychosocial Adjunctive Treatment for Hypersomnia (PATH)

Primary Purpose

Narcolepsy, Idiopathic Hypersomnia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cognitive-Behavior Therapy for Hypersomnia (CBT-H)
Sponsored by
Northwestern University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Narcolepsy focused on measuring Hypersomnia, narcolepsy, idiopathic hypersomnia, psychosocial, cognitive-behavior therapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Males and females age 18 and older.
  2. Meets criteria for Narcolepsy (Type I or II) or Idiopathic Hypersomnia (IH).
  3. Moderate to severe symptoms of depression.
  4. Established standard care for CH at a sleep clinic.

Exclusion Criteria:

  1. Hypersomnia not of central origin.
  2. Current suicidal ideation or intent.
  3. Uncontrolled medical conditions or physical limitations that require immediate medical treatment that would prevent ability to engage in the treatment protocol.
  4. Inability to engage in the treatment protocol due to a psychiatric or cognitive issue.
  5. Untreated moderate-to-severe sleep-related breathing disorder.
  6. Unable to attend intervention sessions due to accessibility or availability.

Sites / Locations

  • Center for Circadian and Sleep Medicine, Northwestern University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

CBT-H (Individual format)

CBT-H (Group format)

Arm Description

Individual CBT-H consists of 6 weekly sessions that are conducted one-on-one with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes.

Group-based CBT-H consists of 6 weekly sessions that are conducted in groups with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes. The treatment package consists of the same cognitive and behavioral modules as the individual CBT-H. However, participants are also provided the opportunity to share their experiences and provide peer support in the group format.

Outcomes

Primary Outcome Measures

Patient Health Questionnaire (PHQ)
The PHQ is a 9-item self-report scale of depressive symptoms that has been validated to assess the severity of depression in clinical practice. PHQ-9 cut scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively.

Secondary Outcome Measures

Patient Reported Outcomes Measurement Information System (PROMIS) Self Efficacy Scale
Measures general self-efficacy, self-efficacy for managing emotions, self-efficacy for managing social interactions, self-efficacy for managing symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting better self-efficacy.
Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale
Measures depressive symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more anxiety symptoms.
Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale
Measures anxiety symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more anxiety symptoms.
Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Scale
Measures sleep disturbances using Computer Adaptive Testing (CAT) with higher scores reflecting more sleep disturbance.
Patient Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment Scale
Measures sleep-related impairment using Computer Adaptive Testing (CAT) with higher scores reflecting worse outcomes.
Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale
Measures fatigue using Computer Adaptive Testing (CAT) with higher scores reflecting worse outcomes.
Patient Reported Outcomes Measurement Information System (PROMIS) Phyiscal Function Scale
Measures physical function using Computer Adaptive Testing (CAT) with higher scores reflecting better physical function.
Epworth Sleepiness Scale (ESS)
The ESS consists of eight questions rated from 0 to 3, with higher scores indicating greater likelihood of falling asleep. Total scores of 10 or greater reflect excessive daytime sleepiness.
Functional Outcomes of Sleep Questionaire (FOSQ)
The FOSQ assesses the impact of sleepiness on daily behaviors and quality of life. It is comprised of 30 items divided into five subscales: activity level, vigilance, intimate and sexual relationships, general productivity, and social outcome. Items are rated from 1 to 4, with higher score reflecting better functioning.

Full Information

First Posted
April 3, 2019
Last Updated
November 19, 2019
Sponsor
Northwestern University
search

1. Study Identification

Unique Protocol Identification Number
NCT03904238
Brief Title
Psychosocial Adjunctive Treatment for Hypersomnia (PATH)
Official Title
Psychosocial Adjunctive Treatment for Hypersomnia (PATH): A Pilot Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2019
Overall Recruitment Status
Completed
Study Start Date
December 10, 2018 (Actual)
Primary Completion Date
September 30, 2019 (Actual)
Study Completion Date
October 7, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwestern University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Current pharmacological treatments for chronic hypersomnia (narcolepsy, idiopathic hypersomnia) can effectively reduce excessive daytime sleepiness but a high proportion of patients experience depressive symptoms and poor health-related quality of life. Unfortunately, there are currently no psychosocial interventions that directly addresses this issue. Therefore, the overall goal of this project is to gather initial outcome data and work out methodological issues to determine if a future pragmatic clinical trial is warranted.
Detailed Description
Chronic hypersomnia (CH) is a serious and debilitating condition involving persistent excessive daytime sleepiness (EDS) and includes narcolepsy and idiopathic hypersomnia (IH). Currently, pharmacotherapy is the only empirically-validated treatment for reducing EDS in this patient population but the burden of long-term management and adverse effects of the medication lead to poor health-related quality of life (HRQoL) and elevations in depressive symptoms Evidence-based psychosocial interventions have been developed in other areas to improve HRQoL related to chronic illnesses, such as cancer and chronic pain. These interventions typically involve a package of cognitive and behavioral techniques teaching coping skills (e.g., emotion-focused and problem-focused coping), behavioral management of the chronic illness symptoms (e.g., relaxation for pain management), and other strategies to improve psychosocial functioning (e.g., mindfulness). However, no such interventions have been developed or used for people with CH. Therefore, a major research gap exists for an empirically-validated psychosocial intervention which is aimed directly at improving emotional functioning and HRQoL for people with CH. The purpose of this project is to develop a cognitive-behavioral treatment for hypersomnia (CBT-H) and conducting a feasibility trial of CBT-H. The specific aims for this project are to: 1) develop and refine a treatment protocol for CBT-H; 2) identify the optimal delivery format of CBT-H; and 3) gather feasibility data on recruitment, retention, and selection criteria for a future clinical trial. The overall significance of this project is to improve the quality of care for people with CH by using a psychosocial intervention with medical management of hypersomnia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Narcolepsy, Idiopathic Hypersomnia
Keywords
Hypersomnia, narcolepsy, idiopathic hypersomnia, psychosocial, cognitive-behavior therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants are assigned to receive CBT-H in one of two formats: 1) individually or 2) small groups. However, the contents of the intervention are the same.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
35 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CBT-H (Individual format)
Arm Type
Experimental
Arm Description
Individual CBT-H consists of 6 weekly sessions that are conducted one-on-one with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes.
Arm Title
CBT-H (Group format)
Arm Type
Experimental
Arm Description
Group-based CBT-H consists of 6 weekly sessions that are conducted in groups with a study therapist using live videoconferencing or in-person. Each session is expected to last about 45 to 60 minutes. The treatment package consists of the same cognitive and behavioral modules as the individual CBT-H. However, participants are also provided the opportunity to share their experiences and provide peer support in the group format.
Intervention Type
Behavioral
Intervention Name(s)
Cognitive-Behavior Therapy for Hypersomnia (CBT-H)
Intervention Description
The CBT-H intervention consists of 6 weekly sessions that are conducted either individually or in small groups. Each session is expected to last about 45 to 60 minutes and will be delivered a study therapist using live videoconferencing or in-person. The treatment package consists of cognitive and behavioral modules that include education about hypersomnia, coping skills training, emotion regulation regarding the perceived limitations of living with chronic hypersomnia (e.g., "I cannot live a full life because of my illness"), and behavioral techniques using scheduled naps, sleep hygiene, and regularizing sleep schedules at night which are on the current optional recommendations for hypersomnia.
Primary Outcome Measure Information:
Title
Patient Health Questionnaire (PHQ)
Description
The PHQ is a 9-item self-report scale of depressive symptoms that has been validated to assess the severity of depression in clinical practice. PHQ-9 cut scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively.
Time Frame
Change from Baseline PHQ at 6 weeks (Post-treatment)
Secondary Outcome Measure Information:
Title
Patient Reported Outcomes Measurement Information System (PROMIS) Self Efficacy Scale
Description
Measures general self-efficacy, self-efficacy for managing emotions, self-efficacy for managing social interactions, self-efficacy for managing symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting better self-efficacy.
Time Frame
Baseline to post-treatment (6 weeks)
Title
Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale
Description
Measures depressive symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more anxiety symptoms.
Time Frame
Baseline to post-treatment (6 weeks)
Title
Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale
Description
Measures anxiety symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more anxiety symptoms.
Time Frame
Baseline to post-treatment (6 weeks)
Title
Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Scale
Description
Measures sleep disturbances using Computer Adaptive Testing (CAT) with higher scores reflecting more sleep disturbance.
Time Frame
Baseline to post-treatment (6 weeks)
Title
Patient Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment Scale
Description
Measures sleep-related impairment using Computer Adaptive Testing (CAT) with higher scores reflecting worse outcomes.
Time Frame
Baseline to post-treatment (6 weeks)
Title
Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale
Description
Measures fatigue using Computer Adaptive Testing (CAT) with higher scores reflecting worse outcomes.
Time Frame
Baseline to post-treatment (6 weeks)
Title
Patient Reported Outcomes Measurement Information System (PROMIS) Phyiscal Function Scale
Description
Measures physical function using Computer Adaptive Testing (CAT) with higher scores reflecting better physical function.
Time Frame
Baseline to post-treatment (6 weeks)
Title
Epworth Sleepiness Scale (ESS)
Description
The ESS consists of eight questions rated from 0 to 3, with higher scores indicating greater likelihood of falling asleep. Total scores of 10 or greater reflect excessive daytime sleepiness.
Time Frame
Baseline to post-treatment (6 weeks)
Title
Functional Outcomes of Sleep Questionaire (FOSQ)
Description
The FOSQ assesses the impact of sleepiness on daily behaviors and quality of life. It is comprised of 30 items divided into five subscales: activity level, vigilance, intimate and sexual relationships, general productivity, and social outcome. Items are rated from 1 to 4, with higher score reflecting better functioning.
Time Frame
Baseline to post-treatment (6 weeks)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females age 18 and older. Meets criteria for Narcolepsy (Type I or II) or Idiopathic Hypersomnia (IH). Moderate to severe symptoms of depression. Established standard care for CH at a sleep clinic. Exclusion Criteria: Hypersomnia not of central origin. Current suicidal ideation or intent. Uncontrolled medical conditions or physical limitations that require immediate medical treatment that would prevent ability to engage in the treatment protocol. Inability to engage in the treatment protocol due to a psychiatric or cognitive issue. Untreated moderate-to-severe sleep-related breathing disorder. Unable to attend intervention sessions due to accessibility or availability.
Facility Information:
Facility Name
Center for Circadian and Sleep Medicine, Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32804069
Citation
Ong JC, Dawson SC, Mundt JM, Moore C. Developing a cognitive behavioral therapy for hypersomnia using telehealth: a feasibility study. J Clin Sleep Med. 2020 Dec 15;16(12):2047-2062. doi: 10.5664/jcsm.8750.
Results Reference
derived

Learn more about this trial

Psychosocial Adjunctive Treatment for Hypersomnia (PATH)

We'll reach out to this number within 24 hrs